These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 1722586)

  • 1. [Prenatal screening for trisomy 21 in maternal blood. Focus].
    Koulischer L; Schoos R; Verloes A; Herens C
    Rev Med Liege; 1991 Dec; 46(12):625-32. PubMed ID: 1722586
    [No Abstract]   [Full Text] [Related]  

  • 2. Pregnancy outcomes of women with positive serum screening results for Down syndrome and trisomy 18.
    Summers AM; Huang T; Wyatt PR
    Prenat Diagn; 2002 Mar; 22(3):269-71. PubMed ID: 11920909
    [No Abstract]   [Full Text] [Related]  

  • 3. [Maternal serum markers of fetal trisomy 21].
    Muller F; Bussières L; Chevallier B
    Presse Med; 1995 Sep; 24(27):1265-9. PubMed ID: 7501610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prenatal cytogenetic screening.
    Simpson JL
    Ultrasound Obstet Gynecol; 1995 Jan; 5(1):3-5. PubMed ID: 7531607
    [No Abstract]   [Full Text] [Related]  

  • 5. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening.
    Haddow JE; Palomaki GE; Knight GJ; Cunningham GC; Lustig LS; Boyd PA
    N Engl J Med; 1994 Apr; 330(16):1114-8. PubMed ID: 7510852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience on triple markers serum screening for Down's syndrome fetus in Hat Yai, Regional Hospital.
    Lamlertkittikul S; Chandeying V
    J Med Assoc Thai; 2007 Oct; 90(10):1970-6. PubMed ID: 18041410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of Down syndrome: the Jerusalem experience.
    Bach G; Ben-Neriah Z; Sagi M
    Isr J Med Sci; 1993 Aug; 29(8):468-70. PubMed ID: 7691779
    [No Abstract]   [Full Text] [Related]  

  • 8. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization.
    McDuffie RS; Haverkamp AD; Stark CF; Haverkamp C; Barth CK
    J Matern Fetal Med; 1996; 5(2):70-3. PubMed ID: 8796771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimates for the sensitivity and false-positive rates for second trimester serum screening for Down syndrome and trisomy 18 with adjustment for cross-identification and double-positive results.
    Benn PA; Ying J; Beazoglou T; Egan JF
    Prenat Diagn; 2001 Jan; 21(1):46-51. PubMed ID: 11180240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down syndrome: prenatal risk assessment and diagnosis.
    Newberger DS
    Am Fam Physician; 2000 Aug; 62(4):825-32, 837-8. PubMed ID: 10969860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maternal serum screening.
    Carroll JC
    Can Fam Physician; 1994 Oct; 40():1756-64. PubMed ID: 7524838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The prenatal diagnosis of Down's syndrome based on the biochemical screening of maternal serum markers].
    Arbuzova SB; Nikolenko MI; Khlevnaia LA; Fedotova OO; Solov'eva VD; Malova SA
    Tsitol Genet; 1998; 32(1):66-71. PubMed ID: 9695254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Periodic health examination, 1996 update: 1. Prenatal screening for and diagnosis of Down syndrome. Canadian Task Force on the Periodic Health Examination.
    Dick PT
    CMAJ; 1996 Feb; 154(4):465-79. PubMed ID: 8630836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amniocentesis. The experience in a district hospital.
    Ogueh O; Baffour M; Hibbert K; McMillan L
    Clin Exp Obstet Gynecol; 1996; 23(3):133-5. PubMed ID: 8894318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Blood screening for Down's syndrome in women under 35 years of age with an age-independent index].
    Benz R; Müller U; Krahner-Pilat M; Wagner-Geuder S; Terinde R
    Z Geburtshilfe Perinatol; 1993; 197(5):205-8. PubMed ID: 7505992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum alpha-fetoprotein, hCG, and unconjugated estriol.
    Cheng EY; Luthy DA; Zebelman AM; Williams MA; Lieppman RE; Hickok DE
    Obstet Gynecol; 1993 Jan; 81(1):72-7. PubMed ID: 7677967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Screening for congenital anomalies in mid-term pregnancy. Prospective epidemiologic study. Fetal trisomy].
    Tóth-Pál E; Oroszné Nagy J; Papp C; Szabó M; Veress L; Török O; Tóth Z; Papp Z
    Orv Hetil; 1995 Feb; 136(9):483-9. PubMed ID: 7535413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apparently low maternal serum inhibin A levels in second-trimester screening.
    Lambert-Messerlian GM; Keren DF; Raphtis CS; Byberg K; Canick JA
    Prenat Diagn; 2005 Oct; 25(10):967-8. PubMed ID: 16193465
    [No Abstract]   [Full Text] [Related]  

  • 19. Triploidy identified through second-trimester serum screening.
    Huang T; Alberman E; Wald N; Summers AM
    Prenat Diagn; 2005 Mar; 25(3):229-33. PubMed ID: 15791661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maternal serum screening for aneuploid pregnancy by alpha-fetoprotein, hCG, and unconjugated estriol.
    Heyl PS; Miller W; Canick JA
    Obstet Gynecol; 1990 Dec; 76(6):1025-31. PubMed ID: 1700348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.